HOPKINTON — Lonza Hopkinton Inc. has hired Heritage Equity Partners of Maryland to seek a buyer for the pair of former biomedical manufacturing facilities at 97 South St.
The two buildings, each 64,000 square feet, were vacated last year by Lonza Ltd., a Swiss-based pharmaceutical company. The company also plans to sell equipment and sublease the facility. A company spokeswoman said Lonza has “no plans to further operate the business.”
About two-thirds of Lonza’s employees in Hopkinton lost their jobs with the shutdown, and the plant’s assets and activities were consolidated with Lonza’s facility in Visp, Switzerland.
The facilities “are ideally suited for microbial fermentation and purification of bulk biopharmaceutical drug substance, or potentially vaccines, cell therapy, oral grade pharmaceuticals or similar products,” according to a company press release. “The facility is also potentially suitable for mammalian production, laboratory testing activities, research and development work, nutraceuticals, enzymes, animal health, cosmetics or food processing products.”